Skip to main content
Premium Trial:

Request an Annual Quote

PositiveID Board Approves 1-for-25 Reverse Stock Split

NEW YORK (GenomeWeb News) – PositiveID said today its board has approved a 1-for-25 reverse stock split, commencing at the start of trading on April 23.

As a result of the reverse split, the number of PositiveID shares will be reduced to about 15 million shares. The company's ticker symbol will be PSIDD for about 20 trading days after the split to designate it is trading on a post-reverse split basis.

The company trades on the Over-The-Counter Bulletin Board.

PositiveID has focused on its molecular diagnostic technologies for biothreat detection and rapid medical testing during the past two years, and the Delray Beach, Fla.-based firm said that the reverse split "could enhance the appeal of its common stock to the financial community," including institutional investors, potential new strategic partners, and the general investing public

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.